In conclusion, the study’s results provide compelling evidence for the therapeutic potential of Kae in NASH treatment, as it appears to restore balance within the liver by modulating the NLRP3 inflammasome pathway. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.